Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumabPier Francesco Ferrucci, Chiara Martinoli, Ester Simeone et al.|Annals of Oncology|2016Cited by 398
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohortPaolo A. Ascierto, Paola Queirolo, Ester Simeone et al.|Journal of Translational Medicine|2014Cited by 164
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumabPier Francesco Ferrucci, Chiara Martinoli, Paolo A. Ascierto et al.|Annals of Oncology|2017Cited by 50
Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.Paola Queirolo, Paolo A. Ascierto, Francesco Spagnolo et al.|Journal of Clinical Oncology|2013Cited by 11
The European Ipilimumab Expanded Access Programme (EAP): Efficacy and Safety Data from the Italian Cohort of Patients with Pretreated, Advanced MelanomaPaolo A. Ascierto, Paola Queirolo, Michele Del Vecchio et al.|Annals of Oncology|2012Cited by 6